Mapping Drug Responses Through Multi-Omics: A New Era of Bioinformatics in Precision Medicine

<p><span>The advent of precision medicine has instigated a paradigm shift in disease treatment, emphasizing the customization of therapies based on individual molecular profiles. Central to this transformation is the integration of multi-omics data encompassing genomics, transcriptomics, proteomics, metabolomics, epigenomics, and more to elucidate the complex biological networks that influence drug response. This review synthesizes the current landscape of multi-omics approaches in precision pharmacology, concentrating on their application in understanding and predicting variability in therapeutic efficacy and toxicity. We commence by examining the individual omics layers pertinent to pharmacodynamics and pharmacokinetics, highlighting how their integration yields synergistic insights that surpass the limitations of single-omics strategies. The challenges posed by heterogeneous data types, technical variability, and integration complexity are critically assessed. In response, we evaluate computational methodologies developed to manage and analyse multi-omics datasets, including advanced machine learning and AI-driven platforms. Tools such as iCluster, MOFA, and DeepMO are discussed for their role in enhancing the accuracy of drug response predictions. We underscore key case studies demonstrating the clinical impact of multi-omics, such as in EGFR-targeted therapy and BRCA-mutated cancers, and explore emerging areas like the role of the microbiome and single-cell multi-omics in revealing intra-tumour heterogeneity. Finally, we address ethical considerations, data privacy, and the necessity for standardization. This review envisions a future where multi-omics-guided precision medicine optimizes drug efficacy and democratizes personalized care across diverse populations</span><span>.</span></p>